Methods	Six-week double-blind, randomised, two-site study.
Participants	Inpatients fulfilling DSM-III-R criteria for major depressive disorder without psychotic features, with a score of at least 18 on the HDRS-17. Age range: 18-70 years. Exclusion criteria: high suicide risk, other psychiatric diagnosis, somatic disease which could controindicate treatment with fluoxetine or maprotiline, history of hypersensitivity, severe allergies, multiple severe reactions to drugs, lactation, pregnancy or pregnancy wish, MAOI use within 2 weeks before starting the trial
Interventions	Fluoxetine: 30 participants. Maprotiline: 35 participants. Fluoxetine dose range: 40-80. Maprotiline dose range: 50-150. Only oxazepam was allowed as hypnotic or anxiolitic, if absolutely required
Outcomes	Hamilton Rating Scale for Depression (HDRS-17), Raskin Depression Scale, Covi Anxiety Scale, CGI Severity and Improvement,
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear